has been acquired by

Contact Us

On May 6, 2020, BioNTech (Nasdaq: BNTX, “BioNTech” or “the Company”) announced the closing of the Neon Therapeutics, Inc. (Nasdaq: NTGN, “Neon”) acquisition through an all-stock transaction. The merger agreement was first announced on January 16, 2020. The new subsidiary based in Cambridge, Massachusetts, will operate under the name of BioNTech US Inc. and serve as BioNTech’s U.S. headquarters. As of May 7, 2020, Neon’s common stock will no longer be available for trading.

Duff & Phelps served as an independent financial advisor to the board of directors of Neon Therapeutics, Inc. and provided a fairness opinion in connection with the transaction.

About Neon Therapeutics, Inc.
Neon Therapeutics, Inc. is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Goodwin Procter LLP served as a legal advisor to Neon Therapeutics, Inc. 


About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Eli Lilly and Company, Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant, Fosun Pharma, and Pfizer. Covington & Burling LLP served as a legal advisor to BioNTech.

2020-05-20T00:00:00.0000000 /-/media/assets/images/transactions/2020/neon-therapeutics.png /-/media/assets/images/transactions/2018/biontech.jpg /about-us/transactions/fairness-opinions/fairness-opinion-neon-therapeutics case study {6B6F3B01-98A6-4BC2-B2CD-CBD127447FB5} {D3AE3EC6-3254-4441-B111-1AF8D558906C} {D59CA77E-C551-45A3-BE89-F567210C5A60} {DC6234F2-03B5-4F3D-9CDE-146A80B170AD} {6CF79F93-78F0-4372-B361-7FE304102FFC} {DF0A8D82-EB98-4261-8951-BF842E034FA8} {B871D4F9-5FCB-40B9-8710-871A30B710AB}

Other Areas We Can Help

Transaction Advisory Services

Seamless analytical advisory through the deal continuum, from transaction origination to closing.

Transaction Advisory Services
Corporate Finance

Corporate Finance

Comprehensive support throughout mergers and acquisitions and other corporate transactions.

Corporate Finance
Healthcare M&A Advisory

Healthcare M&A

Healthcare expertise for middle-market M&A transactions.

Healthcare M&A
Valuation Services

Strategic Value Advisory

Assistance evaluating strategic alternatives and identifying growth strategies.

Strategic Value Advisory

Related Case Studies

Insights

M&A Advisory

Canadian M&A Insights – Summer 2020

M&A Advisory
M&A Advisory

European Chemicals Update – Q3 2020

M&A Advisory
M&A Advisory

Healthcare Services Sector Update – June 2020

M&A Advisory
M&A Advisory

Staffing Industry Insights – Summer 2020

M&A Advisory

News